Literature DB >> 26542410

Giant extragenital Bowen's disease.

Ilko Bakardzhiev1, Anastasiya Atanasova Chokoeva2, Georgi Tchernev3,4.   

Abstract

Giant extragenital forms of Morbus Bowen are extremely rare. The already described cases in the word literature are most commonly with periungual localization, as well as located on the foot and neck area. The clinical manifestation is presented most commonly by non-specific erythematous to erythematous-squamous plaques or papules, which is confusing to the clinician. From the pathogenic point of view, it is important to be confirmed or rejected the presence of human papilloma viruses (HPVs) in each case of affected patient, as this information is mandatory in respect to the adequate selection of the subsequent regimen. If HPVs are detected, systemic antiviral therapy could be initiated to reduce the size of the lesions before subsequent surgical eradication. A postoperative prevention through vaccination could be also considered additionally. In cases of HPV-negative giant extragenital forms of Morbus Bowen (as in the described patient), the focus should be on local immunomodulation by substances such as imiquimod, which reduce the size of the lesions, thereby creating optimal opportunities for their future surgical eradication. Other possible options described in the literature include topical application of 5-fluorouracil, photodynamic therapy, cryotherapy, and laser therapy (carbon dioxide laser). The choice of the most appropriate regimen should have been an individual decision of the clinician, considering also the location and the extent of the lesion.

Entities:  

Keywords:  Bowen; Conservative approach; HPV; Imiquimod; Surgical approach

Mesh:

Year:  2015        PMID: 26542410     DOI: 10.1007/s10354-015-0396-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  9 in total

1.  Bowen disease of the eyelid successfully treated with imiquimod.

Authors:  Paul A Brannan; Heidi K Anderson; Robert C Kersten; Dwight R Kulwin
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2005-07       Impact factor: 1.746

2.  Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions.

Authors:  M Truchuelo; M Fernández-Guarino; B Fleta; J Alcántara; P Jaén
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-07-09       Impact factor: 6.166

3.  [Treatment of paraungual HPV73-positive Bowen disease with imiquimod cream].

Authors:  P Weisenseel; J Prinz; H Korting
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

4.  Imiquimod 5% cream: a new treatment for Bowen's disease.

Authors:  I Mandekou-Lefaki; F Delli; Th Koussidou-Eremondi; O Mourellou-Tsatsou; A Dionyssopoulos
Journal:  Int J Tissue React       Date:  2005

5.  [Detection of human papillomavirus in cutaneous extragenital Bowen's disease in immunocompetent patients].

Authors:  A Lampert; C Pauwels; C Duboucher; G Morel; J D Poveda; G Périé
Journal:  Ann Dermatol Venereol       Date:  2000-01       Impact factor: 0.777

6.  Human papillomaviruses of the mucosal type are present in some cases of extragenital Bowen's disease.

Authors:  S Zheng; A Adachi; M Shimizu; S-I Shibata; S Yasue; A Sakakibara; M Sugiura; T Nagasaka; Y Tomita
Journal:  Br J Dermatol       Date:  2005-06       Impact factor: 9.302

Review 7.  The mechanistic basis of arsenicosis: pathogenesis of skin cancer.

Authors:  Katherine M Hunt; Ritesh K Srivastava; Craig A Elmets; Mohammad Athar
Journal:  Cancer Lett       Date:  2014-08-27       Impact factor: 8.679

8.  Cutaneous Bowen's disease. An analysis of 1001 cases according to age, sex, and site.

Authors:  S Kossard; R Rosen
Journal:  J Am Acad Dermatol       Date:  1992-09       Impact factor: 11.527

Review 9.  Interventions for cutaneous Bowen's disease.

Authors:  Fiona J Bath-Hextall; Rubeta N Matin; David Wilkinson; Jo Leonardi-Bee
Journal:  Cochrane Database Syst Rev       Date:  2013-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.